Logo image of CMRX

CHIMERIX INC (CMRX) Stock Fundamental Analysis

NASDAQ:CMRX - Nasdaq - US16934W1062 - Common Stock - Currency: USD

5.15  -0.02 (-0.39%)

After market: 5.18 +0.03 (+0.58%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CMRX. CMRX was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CMRX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CMRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CMRX had negative earnings in the past year.
In the past year CMRX has reported a negative cash flow from operations.
In the past 5 years CMRX reported 4 times negative net income.
In the past 5 years CMRX always reported negative operating cash flow.
CMRX Yearly Net Income VS EBIT VS OCF VS FCFCMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M

1.2 Ratios

CMRX has a Return On Assets (-52.68%) which is comparable to the rest of the industry.
The Return On Equity of CMRX (-61.57%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -52.68%
ROE -61.57%
ROIC N/A
ROA(3y)-49.77%
ROA(5y)-59%
ROE(3y)-76.39%
ROE(5y)-78.16%
ROIC(3y)N/A
ROIC(5y)N/A
CMRX Yearly ROA, ROE, ROICCMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

1.3 Margins

CMRX's Gross Margin of 203.77% is amongst the best of the industry. CMRX outperforms 99.64% of its industry peers.
CMRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 203.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMRX Yearly Profit, Operating, Gross MarginsCMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K -20K -25K

More info and screens

8

2. Health

2.1 Basic Checks

CMRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CMRX has been increased compared to 1 year ago.
CMRX has more shares outstanding than it did 5 years ago.
CMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMRX Yearly Shares OutstandingCMRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
CMRX Yearly Total Debt VS Total AssetsCMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

CMRX has an Altman-Z score of 3.51. This indicates that CMRX is financially healthy and has little risk of bankruptcy at the moment.
CMRX has a Altman-Z score of 3.51. This is in the better half of the industry: CMRX outperforms 76.91% of its industry peers.
CMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.51
ROIC/WACCN/A
WACC9.44%
CMRX Yearly LT Debt VS Equity VS FCFCMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 6.33 indicates that CMRX has no problem at all paying its short term obligations.
The Current ratio of CMRX (6.33) is better than 63.41% of its industry peers.
A Quick Ratio of 6.33 indicates that CMRX has no problem at all paying its short term obligations.
CMRX has a better Quick ratio (6.33) than 63.77% of its industry peers.
Industry RankSector Rank
Current Ratio 6.33
Quick Ratio 6.33
CMRX Yearly Current Assets VS Current LiabilitesCMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.08% over the past year.
The Revenue for CMRX has decreased by -85.93% in the past year. This is quite bad
CMRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -46.25% yearly.
EPS 1Y (TTM)2.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.7%
Revenue 1Y (TTM)-85.93%
Revenue growth 3Y-60.78%
Revenue growth 5Y-46.25%
Sales Q2Q%136.36%

3.2 Future

CMRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.64% yearly.
The Revenue is expected to grow by 269.26% on average over the next years. This is a very strong growth
EPS Next Y-9.54%
EPS Next 2Y2.41%
EPS Next 3Y9.05%
EPS Next 5Y25.64%
Revenue Next Year-37.6%
Revenue Next 2Y234.25%
Revenue Next 3Y385.34%
Revenue Next 5Y269.26%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CMRX Yearly Revenue VS EstimatesCMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
CMRX Yearly EPS VS EstimatesCMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CMRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMRX Price Earnings VS Forward Price EarningsCMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMRX Per share dataCMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.41%
EPS Next 3Y9.05%

More info and screens

0

5. Dividend

5.1 Amount

CMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHIMERIX INC

NASDAQ:CMRX (2/21/2025, 8:10:15 PM)

After market: 5.18 +0.03 (+0.58%)

5.15

-0.02 (-0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners54.92%
Inst Owner Change-99.57%
Ins Owners7.04%
Ins Owner Change3.41%
Market Cap463.19M
Analysts85.45
Price Target8.57 (66.41%)
Short Float %4.28%
Short Ratio0.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.98%
Min EPS beat(2)-7.74%
Max EPS beat(2)3.77%
EPS beat(4)2
Avg EPS beat(4)0.32%
Min EPS beat(4)-11.63%
Max EPS beat(4)16.87%
EPS beat(8)5
Avg EPS beat(8)0.96%
EPS beat(12)7
Avg EPS beat(12)-9.21%
EPS beat(16)8
Avg EPS beat(16)-21.2%
Revenue beat(2)1
Avg Revenue beat(2)18.17%
Min Revenue beat(2)-66.01%
Max Revenue beat(2)102.35%
Revenue beat(4)1
Avg Revenue beat(4)-39.28%
Min Revenue beat(4)-100%
Max Revenue beat(4)102.35%
Revenue beat(8)3
Avg Revenue beat(8)-13.95%
Revenue beat(12)5
Avg Revenue beat(12)545.06%
Revenue beat(16)7
Avg Revenue beat(16)415.12%
PT rev (1m)0%
PT rev (3m)22.93%
EPS NQ rev (1m)0.77%
EPS NQ rev (3m)-25.07%
EPS NY rev (1m)-0.92%
EPS NY rev (3m)-5.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-96.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2913.15
P/FCF N/A
P/OCF N/A
P/B 3.41
P/tB 3.41
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS1.51
TBVpS1.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.68%
ROE -61.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 203.77%
FCFM N/A
ROA(3y)-49.77%
ROA(5y)-59%
ROE(3y)-76.39%
ROE(5y)-78.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 139.77%
Cap/Sales 77.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.33
Quick Ratio 6.33
Altman-Z 3.51
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)97.11%
Cap/Depr(5y)66.98%
Cap/Sales(3y)12.76%
Cap/Sales(5y)8.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.7%
EPS Next Y-9.54%
EPS Next 2Y2.41%
EPS Next 3Y9.05%
EPS Next 5Y25.64%
Revenue 1Y (TTM)-85.93%
Revenue growth 3Y-60.78%
Revenue growth 5Y-46.25%
Sales Q2Q%136.36%
Revenue Next Year-37.6%
Revenue Next 2Y234.25%
Revenue Next 3Y385.34%
Revenue Next 5Y269.26%
EBIT growth 1Y3.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.43%
OCF growth 3YN/A
OCF growth 5YN/A